Kidney Cancer

Significant improvement seen in overall survival with pembrolizumab versus placebo and across key subgroups For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the American Society of Clinical Oncology annual Genitourinary...

Findings seen in clear cell renal cell carcinoma patients at very high disease risk after nephrectomy from EVEREST trial For patients with clear cell renal cell carcinoma (RCC) at very high risk for recurrence, adjuvant everolimus is associated with significantly improved recurrence-free survival, according to a study presented at the annual meeting of the European...

Stereotactic body radiation therapy shows promising results in frail patients and oligometastatic cases, offering potential for curative approach and delaying systemic therapy Renal cancer has been considered a radioresistant tumor until recent advancements in radiation oncology. New techniques, such as stereotactic body radiation therapy (SBRT) allow for the safe and precise administration of high-dose radiation...

This study reviewed the role of extracellular vesicles in renal cell carcinoma progression and their potential future clinical applications. Extracellular vesicles (EVs) are nanosized vesicles released into the extracellular spaces by most cell types, including cancer and non-cancer cells. EVs secreted by renal cell carcinoma (RCC) play a role in various steps of cancer progression....

Fascin-1 has a promising role as a biomarker in urologic cancers. Metastasis is the leading cause of poor prognosis in urologic cancers. Early diagnosis and effective treatments for metastatic cancer would improve the survival rate. Fascin-1 is an actin-binding protein involved in cell division, migration, and intercellular interactions. There is frequent upregulation of fascin-1 in...

This study describes a deep learning algorithm model that facilitates accurate prediction of grading and staging of renal clear cell carcinoma and also promotes the optimization of individualized treatment plans. Deep learning algorithms were used to develop a model that allows the prediction of the grading and staging of renal clear cell carcinoma to facilitate...

Individuals with poor- or intermediate-risk advanced sarcomatoid renal cell carcinoma may benefit from better first-line treatment outcomes with nivolumab and ipilimumab than with sunitinib.  Patients suffering from advanced sarcomatoid renal cell carcinoma (sRCC) have poor prognostic outcomes and limited treatment options. The first-line treatment of sRCC comprises nivolumab with ipilimumab (NIVO+IPI), which has greater efficacy...

This study reports that C-reactive protein levels at baseline and after treatment may contribute to predicting the therapeutic efficacy of avelumab plus axitinib in patients suffering from advanced renal cell carcinoma. C-reactive protein (CRP) is an important predictive and prognostic marker in the case of advanced renal cell carcinoma (aRCC). In this clinical trial, the...

Pazopanib was effective and tolerated among patients with advanced renal cell carcinoma and a poor ECOG performance status, and may serve as a potential treatment option for patients who are unable to tolerate or receive immune checkpoint inhibitor drugs. Patients diagnosed with advanced renal cell carcinoma (aRCC) exhibit poor Eastern Cooperative Oncology Group (ECOG) performance...